

## Innovative Medicines Initiative 2 funding opportunities July 2018

The **Innovative Medicines Initiative (IMI)** has now launched its **15<sup>th</sup> and 16<sup>th</sup> Calls for proposals under IMI2**. The Calls give researchers from diverse sectors the opportunity to participate in **ambitious public-private partnerships** that will pave the way for the development of the **medicines of the future**.

### Why apply?

- Obtain **research funding**
- Take part in **scientifically excellent, patient-centric** research
- Join unique consortia involving **top teams** from industry, academia, SMEs, regulators, and others
- Benefit from the **expertise, databases, and infrastructures** of consortium partners
- Boost the **visibility and status** of your organisation in Europe and globally and gain **access to new markets**

### IMI2 – Call 15

IMI2 – Call 15 is a standard, two-stage Call for proposals and includes the following topics:

- Integrated research platforms enabling **patient-centric drug development**
- **Blockchain** enabled healthcare
- Microenvironment imposed signatures in tissue and liquid biopsies in **immune-mediated diseases**
- Emerging **translational safety** technologies and tools for interrogating human immuno-biology
- Development and validation of translational platforms in support of **synaptopathy drug discovery**
- Digital endpoints in **neurodegenerative** and **immune-mediated diseases**

**Read the topic texts:**  
[bit.ly/IMI2Call15](http://bit.ly/IMI2Call15)

**Deadline for short proposals:**  
24 October 2018

Topics under the **IMI2 Antimicrobial Resistance (AMR) Accelerator programme**:

- AMR Accelerator programme Pillar A: Capability Building Network to accelerate and validate scientific discoveries
- AMR Accelerator programme Pillar B: Tuberculosis drug development network to accelerate and validate scientific discoveries and advance the R&D pipeline of new and innovative agents to address the global tuberculosis epidemic

## IMI2 – Call 16

IMI2 – Call 16 is a single-stage Call for proposals.

It is dedicated to Pillar C of the **AMR Accelerator programme** ‘Portfolio Building Networks to advance the R&D pipeline of new and innovative agents to address AMR’.

**Read the topic texts:**

[bit.ly/IMI2Call16](http://bit.ly/IMI2Call16)

**Deadline for proposals:**

24 October 2018

## How to apply

- The rules for and details of how to apply can be found via the Call pages of the IMI website.
- Sign up for / watch recordings of IMI’s webinars on the Call topics, our rules and procedures, and opportunities for SMEs in the new Calls - [bit.ly/Call1516webinars](http://bit.ly/Call1516webinars)
- Follow IMI’s tips for applicants – see [bit.ly/IMItips](http://bit.ly/IMItips)
- Get advice on finding project partners on our partner search page – [bit.ly/IMIfindpartners](http://bit.ly/IMIfindpartners)

## About the Innovative Medicines Initiative

The Innovative Medicines Initiative (IMI) is working to **improve health** by speeding up the development of, and patient access to, **the next generation of medicines**, particularly in areas where there is an **unmet medical or social need**. It does this by **facilitating collaboration** between the key players involved in healthcare research, including universities, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators.

IMI is a **partnership** between **the European Union** and the **European pharmaceutical industry**, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI has a budget of **€3.276 billion** for the period 2014-2020. Half of this comes from the EU. The other half comes from large companies, mostly from the pharmaceutical sector; these do not receive any EU funding, but contribute to the projects ‘in kind’, for example by donating their researchers’ time or providing access to research facilities or resources.

IMI was launched in 2008 and currently has over 100 projects, with more in the pipeline. Some focus on **specific health issues** such as neurological conditions (Alzheimer’s disease, schizophrenia, depression, chronic pain, and autism), diabetes, lung disease, oncology, inflammation & infection, tuberculosis, and obesity.

Others focus on **broader challenges in drug development** like drug and vaccine safety, knowledge management, the sustainability of chemical drug production, the use of stem cells for drug discovery, drug behaviour in the body, the creation of a European platform to discover novel medicines, and antimicrobial resistance. In addition to research projects, IMI supports **education and training** projects.

## Stay in touch

- Visit the IMI website: [www.imi.europa.eu](http://www.imi.europa.eu)
- Sign up to the IMI Newsletter: [bit.ly/IMINewsletter](http://bit.ly/IMINewsletter)
- Follow us on Twitter: [@IMI\\_JU](https://twitter.com/IMI_JU)
- Join the Innovative Medicines Initiative group on LinkedIn: [bit.ly/LinkedInIMI](http://bit.ly/LinkedInIMI)
- E-mail us: [infodesk@imi.europa.eu](mailto:infodesk@imi.europa.eu)
- Get support: [bit.ly/IMIsupport](http://bit.ly/IMIsupport)